Glaucoma Trial, Recruiting NCT07152132 Sponsor: Minia University Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT07152132
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 40 years of age
  • People who have a specific type of glaucoma called primary open-angle glaucoma (POAG) and have previously had an uncomplicated cataract operation where an artificial lens was placed in the eye
  • People whose glaucoma is not adequately controlled by two glaucoma eye drop medications, or who cannot tolerate those medications
  • People whose vision tests show damage in both the upper and lower areas of their visual field, but not in the central area directly in front of them
  • People whose vision field test results fall within a specific range of damage (between -6 dB and -12 dB on a standard vision field measurement)

Who may not be able to join:

  • People who have had a previous surgery for glaucoma
  • People who have used steroid eye drops within the last three months
  • People who have significant cloudiness or scarring of the eye (such as a cloudy cornea) that prevents proper examination of the back of the eye
  • People who have certain eye diseases such as uveitis (inflammation inside the eye)
  • People who have severe conditions affecting the surface of the eye, such as ocular cicatricial pemphigoid (a scarring condition of the eye surface)
  • People who do not have an artificial lens in their eye (aphakic patients)
  • People who have had any eye procedures or operations other than a specific laser procedure called YAG posterior capsulotomy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ahmed M Eid, MD, Minia University Hospital

Phone: 01010045499

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Minia University
Registry
ClinicalTrials.gov
Start date
20 July 2025
Est. completion
30 September 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

evaluate and compare the amount of iop reduction between SC-TSCPC and trabeculectomy with MMC in the management of medically uncontrolled OAG in pseudophakic eyes.; evaluate and compare the degree of safety of SC-TSCPC versus trabeculectomy with MMC in the management of medically uncontrolled OAG in pseudophakic eyes.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov